Clinical trials: CASPR2-Antibody
NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis
Medium-term Effects of Treatments in Autoimmune Encephalitis
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence.
- Conditions
- NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis, CASPR2-Antibody, IgLON5
- Trial name
- META (NCT07133113)
- Testing
- We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
CASPR2-Antibody, Encephalitis Autoimmune
CASPR2 Encephalitis Initial Symptoms
Auto-immune encephalitides involve auto-antibodies targeting the central nervous system, and particularly the synapse and its structure, such as protein CASPR2.
- Conditions
- CASPR2-Antibody, Encephalitis Autoimmune, Paraneoplastic Syndromes
- Trial name
- iniCASPR2 (NCT04653571)
- Testing
- CASPR2 encephalitis
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Hospices Civils de Lyon